Insider Selling Y-mAbs Therapeutics, Inc. COO Sells 5,000 Shares of Stock - MarketBeat
YMAB Stock | USD 5.19 0.37 6.65% |
About 79 percent of Y MAbs' investors are selling. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that quite a large number of traders are terrified. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Insider Selling Y-mAbs Therapeutics, Inc. COO Sells 5,000 Shares of Stock MarketBeat
Read at news.google.com
![]() |
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Y MAbs is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
STRO | Sutro Biopharma | 0.00 |
| ||
PCVX | Vaxcyte | 0.00 |
| ||
SNDX | Syndax Pharmaceuticals | 1.02 |
| ||
EWTX | Edgewise Therapeutics | 2.45 |
| ||
MIRM | Mirum Pharmaceuticals | 3.32 |
| ||
MRUS | Merus BV | 3.44 |
| ||
BLUE | Bluebird Bio | 4.90 |
| ||
BDTX | Black Diamond | 4.98 |
| ||
KRON | Kronos Bio | 5.61 |
| ||
RVMD | Revolution Medicines | 5.89 |
| ||
ARQT | Arcutis Biotherapeutics | 6.28 |
| ||
ERAS | Erasca | 6.57 |
| ||
GBIO | Generation Bio | 6.90 |
| ||
ZNTL | Zentalis Pharmaceuticals | 7.25 |
| ||
TVTX | Travere Therapeutics | 7.48 |
| ||
MRSN | Mersana Therapeutics | 7.69 |
| ||
PASG | Passage Bio | 7.69 |
| ||
DAWN | Day One | 8.94 |
| ||
CCCC | C4 Therapeutics | 11.44 |
| ||
LRMR | Larimar Therapeutics | 12.54 |
|
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |